Abstract
TP53 is a tumor suppressor gene which is commonly mutated in various cancers including breast cancer. Alterations in the gene lead to an altered expression of various genes that are directly or indirectly under the transcriptional control of p53. This results in malfunctioning of DNA damage repair pathways, cell-cycle arrest, chromatin remodeling and apoptosis. Different mutations in TP53 gene have been reported in different ethnic groups and exon 4 and intron 3 are reported to be frequently mutated in breast cancer patients especially triplenegative breast cancer. Increased global burden of TP53 mutated breast tumors has paved the path for various therapies targeting p53/TP53. Numerous molecules including nutilins, MI series, RO5693, PRIMA-1, RITA, etc. have been developed. Majority of these restore p53/TP53 function by targeting negative regulators of p53/TP53, wtp53/TP53 (wild-type) and mtp53/TP53 (mutant). Most of these molecules are in the preclinical phase except for two APR-246 and COTI-2 that have progressed to clinical trials. The current review has been compiled with an aim to give an overview of mutations in p53 across various ethnic groups, the effect of these alterations on TP53 function and the therapeutic strategies developed till date targeting p53/TP53 especially in breast cancer.
Keywords: p53, breast cancer, asians, amerindians, therapeutics.
Current Pharmaceutical Design
Title:Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies
Volume: 24 Issue: 30
Author(s): Raman Preet Kaur, Kanika Vasudeva, Roshan Kumar and Anjana Munshi*
Affiliation:
- Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, 151001,India
Keywords: p53, breast cancer, asians, amerindians, therapeutics.
Abstract: TP53 is a tumor suppressor gene which is commonly mutated in various cancers including breast cancer. Alterations in the gene lead to an altered expression of various genes that are directly or indirectly under the transcriptional control of p53. This results in malfunctioning of DNA damage repair pathways, cell-cycle arrest, chromatin remodeling and apoptosis. Different mutations in TP53 gene have been reported in different ethnic groups and exon 4 and intron 3 are reported to be frequently mutated in breast cancer patients especially triplenegative breast cancer. Increased global burden of TP53 mutated breast tumors has paved the path for various therapies targeting p53/TP53. Numerous molecules including nutilins, MI series, RO5693, PRIMA-1, RITA, etc. have been developed. Majority of these restore p53/TP53 function by targeting negative regulators of p53/TP53, wtp53/TP53 (wild-type) and mtp53/TP53 (mutant). Most of these molecules are in the preclinical phase except for two APR-246 and COTI-2 that have progressed to clinical trials. The current review has been compiled with an aim to give an overview of mutations in p53 across various ethnic groups, the effect of these alterations on TP53 function and the therapeutic strategies developed till date targeting p53/TP53 especially in breast cancer.
Export Options
About this article
Cite this article as:
Kaur Preet Raman , Vasudeva Kanika , Kumar Roshan and Munshi Anjana *, Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies, Current Pharmaceutical Design 2018; 24 (30) . https://dx.doi.org/10.2174/1381612824666180926095709
DOI https://dx.doi.org/10.2174/1381612824666180926095709 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Membrane Disrupting Lytic Peptides for Cancer Treatments
Current Pharmaceutical Design The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Recent Advances in the Development of Immunoadhesins for Immune Therapy and as Anti-Infective Agents
Recent Patents on Anti-Infective Drug Discovery The Role of Radiopharmaceuticals in Amiodarone-Induced Thyroid Pathology
Current Radiopharmaceuticals Pharmacokinetic Analysis of Taxane Through a Validated Ultra-High Performance Liquid Chromatography-Synapt Mass Spectrometry (UHPLC-MS/MS ESI-Q-TOF) Method
Current Bioactive Compounds Physiology and Pharmacology of the Vanilloid Receptor
Current Neuropharmacology Modified Polysaccharides as Versatile Materials in Controlled Delivery of Antidegenerative Agents
Current Pharmaceutical Design The Impact of Gynecological Cancer on Reproductive Issues and Pregnancy:Psychological Implications
Current Women`s Health Reviews New Researches about Combinatorial Therapeutic Regimen on Cancer Treatment
Current Cancer Therapy Reviews Pharmacogenomic Approaches to Osteoporosis: 2005 Update
Current Pharmacogenomics The Emerging Role of the Cannabinoid Receptor Family in Peripheral and Neuro-immune Interactions
Current Drug Targets Telomere DNA Binding, Cleavage and Anticancer Activity of [Cu(phendione)(Hpyramol)Cl]
Current Chemical Biology Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Platelet-derived Growth Factor Receptor (PDGFR) Kinase Inhibitors
Current Drug Metabolism Neuroprotective Effects of Nonsteroidal Anti-inflammatory Drugs on Neurodegenerative Diseases
Current Pharmaceutical Design Drug Combinations Enhancing the Antineoplastic Effects of Erlotinib in High-Grade Glioma
Recent Patents on Anti-Cancer Drug Discovery Fighting Alzheimer's Disease and Type 2 Diabetes: Pathological links and Treatment Strategies
CNS & Neurological Disorders - Drug Targets Nanoparticle-based Cerebral Drug-Delivery Systems and Antiangiogenic Approach in Gliomas Treatment
Recent Patents on Nanotechnology Ubiquitylation and Cancer Development
Current Cancer Drug Targets Synergic Study of α-Glucosidase Inhibitory Action of Aloin and its Antioxidant Activity with and without Camel β-Casein and its Peptides
Protein & Peptide Letters Gene Directed Enzyme Prodrug Therapy for Ovarian Cancer: Could GDEPT Become a Promising Treatment Against Ovarian Cancer?
Anti-Cancer Agents in Medicinal Chemistry